Publisher of Iranian Journals and Conference Proceedings

Please waite ..
Publisher of Iranian Journals and Conference Proceedings
Login |Register |Help |عضویت کتابخانه ها

Prevalence of Macrolide-Lincosamide-Streptogramin B (MLSB) Resistance in Staphybcoccus aureus Isolated from Patients in Tehran, Iran

فصلنامه آسیب شناسی ایران، دوره: 4، شماره: 4
Year: 1388
COI: JR_IJP-4-4_003
Language: EnglishView: 433
This Paper With 6 Page And PDF Format Ready To Download

Buy and Download

با استفاده از پرداخت اینترنتی بسیار سریع و ساده می توانید اصل این Paper را که دارای 6 صفحه است به صورت فایل PDF در اختیار داشته باشید.
آدرس ایمیل خود را در کادر زیر وارد نمایید:


Horieh Saderi - Dept. of Microbiology, Shahed University, Tehran, Iran
Parviz Owlia - Dept. of Microbiology, Shahed University, Tehran, Iran
Maryam Eslami - Dept. of Microbiology, Shahed University, Tehran, Iran


Background and Objectives: Staphylococcus aureus is an important cause of nosocomial and community-acquired infections in every region of the world. Clindamycin is one of the alternativeagents used to treat S. aureus infections and accurate identification of clindamycin resistance isimportant to prevent therapeutic failure. Unfortunately, inducible clindamycin resistance is notdetected by standard susceptibility tests. This study aimed to determine the prevalence of themacrolides-lincosamides-streptogramins B (MLSB) resistance in S. aureus isolated in four universityhospitals in Tehran, Iran. Material & Methods: Two hundreds and forty-four non-duplicate clinical isolates of S. aureus [133 methicillin resistant S. aureus (MRSA) and 111 methicillin susceptible (MSSA) S. aureus] werecollected in 2008. Antimicrobial susceptibilities were determined by the D-test.Results: Altogether, 68% and 61.1% of isolates were resistant to erythromycin and clindamycin, respectively; with higher resistance in MRSA isolates compared to MSSA isolates. The constitutiveMLSB (cMLSB) resistance phenotype was recognized in 61.1%, while 5.3% had shown inducibleMLSB (iMLSB) resistance phenotype. Constitutive MLSB resistance phenotype predominated over inducible MLSB resistance phenotype and susceptible phenotype (83.9, 9.3 and 6.8%, respectively)among the MRSA isolates, whereas susceptible phenotype predominated over constitutive MLSBresistance phenotype and inducible MLSB resistance phenotype (62.6, 31.3 and 2%, respectively) among the MSSA isolates. Conclusion: Considering the higher prevalence of clindamycin resistance in MRSA isolates compared MSSA isolates, routine D-test of MRSA isolates is strongly recommended to prevent treatment failure.


Paper COI Code

This Paper COI Code is JR_IJP-4-4_003. Also You can use the following address to link to this article. This link is permanent and is used as an article registration confirmation in the Civilica reference:

How to Cite to This Paper:

If you want to refer to this Paper in your research work, you can simply use the following phrase in the resources section:
Saderi, Horieh and Owlia, Parviz and Eslami, Maryam,1388,Prevalence of Macrolide-Lincosamide-Streptogramin B (MLSB) Resistance in Staphybcoccus aureus Isolated from Patients in Tehran, Iran,

Research Info Management

Certificate | Report | من نویسنده این مقاله هستم

اطلاعات استنادی این Paper را به نرم افزارهای مدیریت اطلاعات علمی و استنادی ارسال نمایید و در تحقیقات خود از آن استفاده نمایید.


The specifications of the publisher center of this Paper are as follows:
Type of center: دانشگاه دولتی
Paper count: 5,534
In the scientometrics section of CIVILICA, you can see the scientific ranking of the Iranian academic and research centers based on the statistics of indexed articles.

New Papers

Share this page

More information about COI

COI stands for "CIVILICA Object Identifier". COI is the unique code assigned to articles of Iranian conferences and journals when indexing on the CIVILICA citation database.

The COI is the national code of documents indexed in CIVILICA and is a unique and permanent code. it can always be cited and tracked and assumed as registration confirmation ID.